{"filing":{"accession_number":"0001903596-26-000235","cik":"0001792941","ticker":"GNVR","company_name":"Genvor Inc","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"gnvr_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1792941/000190359626000235/gnvr_8k.htm"},"events":[{"id":9630,"run_id":8444,"accession_number":"0001903596-26-000235","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.94,"summary":"Genvor Inc appointed Donald Kalkofen as Chief Financial Officer effective May 18, 2026. The appointment includes compensatory arrangements comprising monthly cash compensation of $6,250 plus $7,750 deferred, and stock options for 575,000 shares. Kalkofen brings extensive experience with IPOs and capital markets transactions relevant to the company's development stage.","company_name":"Genvor Inc","ticker":"GNVR","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1308,"accession_number":"0001903596-26-000235","item_number":"5.02","item_title":"Departure of Directors or Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Donald Kalkofen as Chief Financial Officer effective May 18, 2026. While the section also includes detailed compensatory arrangements (monthly cash compensation of $6,250 plus $7,750 deferred, and stock options for 575,000 shares), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance, particularly given Kalkofen's extensive experience with IPOs and capital markets transactions, which appears relevant to Genvor's stage of development.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:23:37.325806+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1309,"accession_number":"0001903596-26-000235","item_number":"8.01","item_title":"Other Events","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mr. Kalkofen as Chief Financial Officer, announced via press release on May 21, 2026. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's leadership and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:23:37.325806+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1308,"accession_number":"0001903596-26-000235","item_number":"5.02","item_title":"Departure of Directors or Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Donald Kalkofen as Chief Financial Officer effective May 18, 2026. While the section also includes detailed compensatory arrangements (monthly cash compensation of $6,250 plus $7,750 deferred, and stock options for 575,000 shares), the principal disclosed action is the appointment of a named executive officer to a C-suite position. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance, particularly given Kalkofen's extensive experience with IPOs and capital markets transactions, which appears relevant to Genvor's stage of development.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:23:37.325806+00:00","company_name":"Genvor Inc","ticker":"GNVR","filing_date":"2026-05-21"},{"id":1309,"accession_number":"0001903596-26-000235","item_number":"8.01","item_title":"Other Events","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mr. Kalkofen as Chief Financial Officer, announced via press release on May 21, 2026. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's leadership and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:23:37.325806+00:00","company_name":"Genvor Inc","ticker":"GNVR","filing_date":"2026-05-21"}]}